Summit Partners Public Asset Management’s Verona Pharma VRNA Stock Holding History

Summit Partners Public Asset Management’s Portfolio VRNA Stock Details VRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-1,400,000	Closed	-$132M	–	224
2025 Q2	$132M	Buy	1,400,000 +500,000	+56%	+$37M	3.35%	4
2025 Q1	$57.1M	Buy	+900,000	New	+$53.8M	1.47%	17

Other funds holding VRNA

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Summit Partners Public Asset Management's VRNA Position: Q4 2025 in Review

Summit Partners Public Asset Management sold out of Verona Pharma (VRNA) in Q4 2025, closing a stake of 1,785,407 shares — an estimated $191M sold.

Summit Partners Public Asset Management first reported a position in VRNA in Q4 2024 and held it in 4 quarters. The position peaked at $203M in Q2 2025. 1 fund tracked by Wall St. Rank holds VRNA as of Q4 2025.

Summit Partners Public Asset Management reported no remaining Verona Pharma position as of Q4 2025 after selling out during the quarter.
Summit Partners Public Asset Management sold 1,785,407 Verona Pharma shares in Q4 2025, an estimated $191M.
Summit Partners Public Asset Management first reported a position in Verona Pharma in Q4 2024 and held it in 4 quarters.
Summit Partners Public Asset Management's Verona Pharma position peaked at $203M in Q2 2025.
1 fund tracked by Wall St. Rank held Verona Pharma as of Q4 2025.

Based on Summit Partners Public Asset Management's 13F filing for Q4 2025, filed 17 Feb 2026.